Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Stephens

Spurgeon

. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol 2015; 6: 242–252.

National Cancer Institute. Mantle cell lymphoma. Surveillance, Epidemiology, and End Results Program Website, http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5357 (2015, accessed 16 November 2015).

Jares

Colomer

Campo

. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–762.

Cheah

Chihara

Romaguera

et al.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 2015; 26: 1175–1179.

Ghielmini

Zucca

. How I treat mantle cell lymphoma. Blood 2009; 114: 1469–1476.

Advani

Buggy

Sharman

et al.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94.

Byrd

Furman

Coutre

et al.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.

Honigberg

Smith

Sirisawad

et al.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107: 13075–13080.

Wang

Rule

Martin

et al.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

10.

Wang

Blum

Martin

et al.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.

11.

Pharmacyclics, LLC. Imbruvica (ibrutinib) (prescribing information), Sunnyvale, CA: Pharmacyclics, LLC, 2017.

12.

US Food and Drug Administration. Expanded access to investigational drugs for treatment use—questions and answers. US Food and Drug Administration Website, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf (2016; accessed 26 July 2016).

13.

Patil

. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res 2016; 7: 4–8.

14.

Dreyling

Jurczak

Jerkeman

et al.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387: 770–778.

To the Editor,A multicenter,open-label,early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma

Abstract

Get full access to this article

References